



December 18, 2009

Thomas Laughren, M.D.
FDA/CDER/ODE1/DPP
White Oak CDER Office Building 22 Rm 4114

RE: IND 63,384; Forms 1571, Serial No. 0020
MAPS study MP8

Dear Director Laughren,

We are submitting a new study to your office,

Please find along with this letter, “A Randomized, Triple-Blind, Phase 2 Pilot Study Comparing 3 Different Doses of MDMA in Conjunction with Manualized Psychotherapy in 16 Veterans with Chronic Posttraumatic Stress Disorder (PTSD).”

FDA form 1571, dated serial number 0020, December 18, 2009

FDA form 1572, dated December 18, 2009

Three copies of the following

Protocol, dated December 17, 2009

Most recent revision of the Investigator’s Brochure, dated December, 2007

Curriculum vitae for all three investigators

Template informed consent, dated December 17, 2008

Draft case report forms (CRFs)

If you have any questions or would like additional information, I would be delighted to be of assistance.

Sincerely,

A handwritten signature in black ink that reads "Rick Doblin". The signature is written in a cursive, flowing style.

Rick Doblin, PhD

Multidisciplinary Association for Psychedelic Studies
MAPS • Rick Doblin • 309 Cedar Street # 2323 Santa Cruz, CA 95060•
Tel: 831-429-6362 • Fax: 831-429-6370 • www.maps.org • rick@maps.org



Executive Director, MAPS

Multidisciplinary Association for Psychedelic Studies
MAPS • Rick Doblin • 309 Cedar Street # 2323 Santa Cruz, CA 95060 •
Tel: 831-429-6362 • Fax: 831-429-6370 • www.maps.org • rick@maps.org